Research ArticleSjögren Syndrome

Increased Interferon Signaling in Vaginal Tissue of Patients With Primary Sjögren Syndrome

Annie Visser, Jolien F. van Nimwegen, Rick Wilbrink, Silvia C. Liefers, Karin van der Tuuk, Marian J.E. Mourits, Gilles F.H. Diercks, Joost Bart, Bert van der Vegt, Léon C. van Kempen, Hendrika Bootsma, Frans G.M. Kroese and Gwenny M. Verstappen
The Journal of Rheumatology July 2024, 51 (7) 687-695; DOI: https://doi.org/10.3899/jrheum.2023-1068

REFERENCES

  1. 1.↵
    1. Brito-Zerón P,
    2. Baldini C,
    3. Bootsma H, et al.
    Sjögren syndrome. Nat Rev Dis Primers 2016;2:16047.
    OpenUrl
  2. 2.↵
    1. Verstappen GM,
    2. Pringle S,
    3. Bootsma H,
    4. Kroese FGM.
    Epithelial–immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis. Nat Rev Rheumatol 2021;17:333-48.
    OpenUrlCrossRef
  3. 3.
    1. Nocturne G,
    2. Mariette X.
    B cells in the pathogenesis of primary Sjögren syndrome. Nat Rev Rheumatol 2018;14:133-45.
    OpenUrlPubMed
  4. 4.↵
    1. Bodewes ILA,
    2. Björk A,
    3. Versnel MA,
    4. Wahren-Herlenius M.
    Innate immunity and interferons in the pathogenesis of Sjögren’s syndrome. Rheumatology 2021;60:2561-73.
    OpenUrl
  5. 5.↵
    1. Haga HJ,
    2. Gjesdal CG,
    3. Irgens LM,
    4. Ostensen M.
    Reproduction and gynaecological manifestations in women with primary Sjögren’s syndrome: a case-control study. Scand J Rheumatol 2005;34:45-8.
    OpenUrlCrossRefPubMed
  6. 6.
    1. Marchesoni D,
    2. Mozzanega B,
    3. De Sandre P,
    4. Romagnolo C,
    5. Gambari PF,
    6. Maggino T.
    Gynaecological aspects of primary Sjogren’s syndrome. Eur J Obstet Gynecol Reprod Biol 1995;63:49-53.
    OpenUrlCrossRefPubMed
  7. 7.
    1. Maddali Bongi SM,
    2. Del Rosso A,
    3. Orlandi M,
    4. Matucci-Cerinic M.
    Gynaecological symptoms and sexual disability in women with primary Sjögren’s syndrome and sicca syndrome. Clin Exp Rheumatol 2013;31:683-90.
    OpenUrlPubMed
  8. 8.↵
    1. Van Nimwegen JF,
    2. Arends S,
    3. Van Zuiden GS,
    4. Vissink A,
    5. Kroese FG,
    6. Bootsma H.
    The impact of primary Sjögren’s syndrome on female sexual function. Rheumatology 2015;54:1286-93.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. McCready JL,
    2. Deary V,
    3. Collins TL,
    4. Lendrem DW,
    5. Hackett KL.
    Coping strategies, illness perceptions, and relationship dynamics contribute to female sexual function and sexual distress in Sjögren’s syndrome. J Sex Med 2023;20:781-91.
    OpenUrl
  10. 10.↵
    1. Robboy SJ,
    2. Mutter GL,
    3. Prat J, et al.
    Robboy’s Pathology of the Female Reproductive Tract, 2nd edition. Amsterdam: Elsevier Limited; 2009.
  11. 11.↵
    1. van Nimwegen JF,
    2. van Der Tuuk K,
    3. Liefers SC, et al.
    Vaginal dryness in primary Sjögren’s syndrome: a histopathological case–control study. Rheumatology 2020;59:2806-15.
    OpenUrl
  12. 12.
    1. Mulherin DM,
    2. Sheeran TP,
    3. Kumararatne DS,
    4. Speculand B,
    5. Luesley D,
    6. Situnayake RD.
    Sjögren’s syndrome in women presenting with chronic dyspareunia. Br J Obstet Gynaecol 1997;104:1019-23.
    OpenUrlCrossRefPubMed
  13. 13.
    1. Skopouli FN,
    2. Papanikolaou S,
    3. Malamou-Mitsi V,
    4. Papanikolaou N,
    5. Moutsopoulos HM.
    Obstetric and gynaecological profile in patients with primary Sjögren’s syndrome. Ann Rheum Dis 1994;53:569-73.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Capriello P,
    2. Barale E,
    3. Cappelli N,
    4. Lupo S,
    5. Teti G.
    Sjogren’s syndrome: clinical, cytological, histological and colposcopic aspects in women. Clin Exp Obstet Gynecol 1988;15;9-12.
    OpenUrlPubMed
  15. 15.↵
    1. Rosen R,
    2. Brown C,
    3. Heiman J, et al.
    The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26:191-208.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Bachmann G.
    Urogenital ageing: an old problem newly recognized. Maturitas 1995;22 Suppl:S1-5.
    OpenUrlPubMed
  17. 17.↵
    1. Chiche L,
    2. Jourde-Chiche N,
    3. Whalen E, et al.
    Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol 2014;66:1583-95.
    OpenUrl
  18. 18.↵
    1. Lambers WM,
    2. De Leeuw K,
    3. Doornbos-van der Meer B,
    4. Diercks GFH,
    5. Bootsma H,
    6. Westra J.
    Interferon score is increased in incomplete systemic lupus erythematosus and correlates with myxovirus-resistance protein A in blood and skin. Arthritis Res Ther 2019;21:260.
    OpenUrl
  19. 19.↵
    1. Verstappen GM,
    2. Gao L,
    3. Pringle S, et al.
    The transcriptome of paired major and minor salivary gland tissue in patients with primary Sjögren’s syndrome. Front Immunol 2021;12:681941.
    OpenUrl
  20. 20.↵
    1. Bankhead P,
    2. Loughrey MB,
    3. Fernández JA, et al.
    QuPath: open source software for digital pathology image analysis. Sci Rep 2017;7:16878.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Thacker SG,
    2. Berthier CC,
    3. Mattinzoli D,
    4. Rastaldi MP,
    5. Kretzler M,
    6. Kaplan MJ.
    The detrimental effects of IFN-α on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. J Immunol 2010;185:4457-69.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Buie JJ,
    2. Renaud LL,
    3. Muise-Helmericks R,
    4. Oates JC.
    IFN-α negatively regulates the expression of endothelial nitric oxide synthase and nitric oxide production: implications for systemic lupus erythematosus. J Immunol 2017;199:1979-88.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Tydén H,
    2. Lood C,
    3. Gullstrand B, et al.
    Endothelial dysfunction is associated with activation of the type I interferon system and platelets in patients with systemic lupus erythematosus. RMD Open 2017;3:e000508.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Nezos A,
    2. Gravani F,
    3. Tassidou A, et al.
    Type I and II interferon signatures in Sjogren’s syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren’s related lymphomagenesis. J Autoimmun 2015;63:47-58.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Hall JC,
    2. Baer AN,
    3. Shah AA, et al.
    Molecular subsetting of interferon pathways in Sjögren’s syndrome. Arthritis Rheumatol 2015; 67:2437-46.
    OpenUrl
  26. 26.↵
    1. Emamian ES,
    2. Leon JM,
    3. Lessard CJ, et al.
    Peripheral blood gene expression profiling in Sjögren’s syndrome. Genes Immun 2009;10:285-96.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Pestka S,
    2. Langer JA,
    3. Zoon KC,
    4. Samuel CE.
    Interferons and their actions. Annu Rev Biochem 1987;56:727-77.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Bodewes ILA,
    2. Al-Ali S,
    3. van Helden-Meeuwsen CG, et al.
    Systemic interferon type I and type II signatures in primary Sjögren’s syndrome reveal differences in biological disease activity. Rheumatology 2018;57:921-30.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Rönnblom L,
    2. Forsgren A,
    3. Alm GV.
    Characterization of interferons induced by bacteria and interferon-producing leukocytes in human peripheral blood. Infect Immun 1983;40:126-32.
    OpenUrlAbstract/FREE Full Text
  30. 30.
    1. Fitzgerald-Bocarsly P.
    Human natural interferon-alpha producing cells. Pharmacol Ther 1993;60:39-62.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Siegal FP,
    2. Kadowaki N,
    3. Shodell M, et al.
    The nature of the principal type 1 interferon-producing cells in human blood. Science 1999;284:1835-7.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Gottenberg JE,
    2. Cagnard N,
    3. Lucchesi C, et al.
    Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren’s syndrome. Proc Natl Acad Sci U S A 2006;103:2770-5.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Rivière E,
    2. Pascaud J,
    3. Virone A, et al.
    Interleukin-7/interferon axis drives T cell and salivary gland epithelial cell interactions in Sjögren’s syndrome. Arthritis Rheumatol 2021;73:631-40.
    OpenUrl
  34. 34.
    1. Barrera MJ,
    2. Aguilera S,
    3. Veerman E, et al.
    Salivary mucins induce a Toll-like receptor 4-mediated pro-inflammatory response in human submandibular salivary cells: are mucins involved in Sjögren’s syndrome? Rheumatology 2015;54:1518-27.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Deshmukh US,
    2. Nandula SR,
    3. Thimmalapura PR,
    4. Scindia YM,
    5. Bagavant H.
    Activation of innate immune responses through Toll-like receptor 3 causes a rapid loss of salivary gland function. J Oral Pathol Med 2009;38:42-7.
    OpenUrlCrossRefPubMed
  36. 36.
    1. Shiboski CH,
    2. Shiboski SC,
    3. Seror R, et al.
    2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol 2017;69:35-45.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

 Request Permissions

Bookmark this article

Jump to section

Keywords

AUTOIMMUNITY
INFLAMMATION
INTERFERONS
physiologic angiogenesis
SJÖGREN SYNDROME
vagina

Keywords